Program
follitropin delta
Also written as “Follitropin delta”, “FE 999049” and “Follitropin Delta (FE 999049)”.
Its studies are mostly in Infertility · Infertility, Female, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ferring Pharmaceuticals | 150 open or running | phase 3since Aug 16, 2013 | Aug 30, 2011 | none ahead |
| Clinique Ovo | 21 open or running | phase 2since Jan 30, 2019 | Jan 30, 2019 | none ahead |
| Dr François Bissonnette | 10 open or running | no phasesince Mar 8, 2018 | Mar 8, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Aug 30, 2011.
- Nov 28, 2014Phase 2 study in InfertilityFerring Pharmaceuticals · NCT02309671 · 159 enrolled · Japan
- Jul 13, 2017Phase 3 study in InfertilityFerring Pharmaceuticals · NCT03228680 · 373 enrolled · Japan
- Sep 14, 2017Phase 3 study in Controlled Ovarian SimulationFerring Pharmaceuticals · NCT03296527 · 1,011 enrolled · China, Korea, Republic of, Taiwan and more
- Mar 8, 2018Dr François Bissonnette’s first study: no phase study in Fertility DisordersNew to Dr François BissonnetteDr François Bissonnette · NCT03483545 · 160 enrolled · Canada
- May 16, 2018Phase 2 study in Controlled Ovarian StimulationFerring Pharmaceuticals · NCT03564509 · 620 enrolled · Belgium, Czechia, Denmark and more
- Oct 24, 20182 phase 3 studiesFerring Pharmaceuticals · NCT03740737, NCT03738618
- Jan 7, 2019Phase 3 study in Infertility, FemaleFerring Pharmaceuticals · NCT03809429 · 437 enrolled · Austria, Denmark, Israel and more
- Jan 30, 2019Clinique Ovo’s first study: phase 2 study in InfertilityNew to Clinique OvoClinique Ovo · NCT03830723 · 110 enrolled · Canada
- Nov 1, 2019Phase 1 study in InfertilityFerring Pharmaceuticals · NCT04150861 · 24 enrolled · China
- Feb 8, 2021Phase 3 study in InfertilityFerring Pharmaceuticals · NCT04773353 · 220 enrolled · India
- Nov 16, 2021Phase 3 study in InfertilityFerring Pharmaceuticals · NCT05263388 · 302 enrolled · Austria, France, Italy and more
- May 30, 2022Phase 2 study in Male Idiopathic InfertilityFerring Pharmaceuticals · NCT05403476 · 4 enrolled · United States, Belgium, Denmark and more
- Dec 6, 2023Phase 3 study in Infertility, FemaleFerring Pharmaceuticals · NCT06173869 · 301 enrolled · China
- May 21, 2025Phase 2 study in IVFClinique Ovo · NCT06997900 · 200 planned · Canada
TargetBeta
“Follicle stimulating hormone receptor agonist”ChEMBL 37, by rule
Other programs on FSHR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| follitropin alfarule | Merck KGaA, Darmstadt, Germany | phase 4 | 26 |
| Follicle Stimulating Hormonerule | glycotope-gmbh | phase 4 | 6 |
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06997900IVF · Canada | 2 | Recruiting | Clinique Ovo | Aug 2026 | 200 |
| NCT06173869Infertility, Female · China | 3 | Completed | Ferring Pharmaceuticals | May 31, 2025 | 301 |
| NCT05403476Male Idiopathic Infertility · United States, Belgium, Denmark and more | 2 | Terminated | Ferring Pharmaceuticals | Oct 5, 2024 | 4 |
| NCT05263388Infertility · Austria, France, Italy and more | 3 | Completed | Ferring Pharmaceuticals | Apr 16, 2024 | 302 |
| NCT04773353Infertility · India | 3 | Completed | Ferring Pharmaceuticals | Dec 12, 2023 | 220 |
| NCT04150861Infertility · China | 1 | Completed | Ferring Pharmaceuticals | Nov 28, 2019 | 24 |
| NCT03830723Infertility · Canada | 2 | Completed | Clinique Ovo | Jan 20, 2021 | 110 |
| NCT03809429Infertility, Female · Austria, Denmark, Israel and more | 3 | Completed | Ferring Pharmaceuticals | Feb 16, 2022 | 437 |
| NCT03740737Infertility · United States | 3 | Completed | Ferring Pharmaceuticals | Nov 11, 2020 | 579 |
| NCT03738618Infertility, Female · United States | 3 | Completed | Ferring Pharmaceuticals | Dec 21, 2020 | 588 |
| NCT03564509Controlled Ovarian Stimulation · Belgium, Czechia, Denmark and more | 2 | Completed | Ferring Pharmaceuticals | Oct 21, 2019 | 620 |
| NCT03483545Fertility Disorders · Canada | – | Completed | Dr François Bissonnette | Jul 31, 2019 | 160 |
| NCT03296527Controlled Ovarian Simulation · China, Korea, Republic of, Taiwan and more | 3 | Completed | Ferring Pharmaceuticals | Jan 3, 2020 | 1,011 |
| NCT03228680Infertility · Japan | 3 | Completed | Ferring Pharmaceuticals | Jun 10, 2019 | 373 |
| NCT02309671Infertility · Japan | 2 | Completed | Ferring Pharmaceuticals | Nov 2015 | 159 |
| NCT01956123Infertility · Belgium, Brazil, Canada and more | 3 | Completed | Ferring Pharmaceuticals | May 2015 | 513 |
| NCT01956110Infertility · Belgium, Brazil, Canada and more | 3 | Completed | Ferring Pharmaceuticals | May 2015 | 1,329 |
| NCT01426386Infertility · Belgium, Czechia, Denmark and more | 2 | Completed | Ferring Pharmaceuticals | Apr 2012 | 265 |
How it is read
Names in the registry
- “Follitropin delta”, 5 entries
- “FE 999049”, 4 entries
- “Follitropin Delta (FE 999049)”, 3 entries
- “Combination therapy : Follitropin delta and HP-hMG”, 1 entry
- “REKOVELLE (Follitropin Delta)”, 1 entry
Conditions, from the studies’ own filings
- Infertility, 11 studies
- Infertility, Female, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.